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Tauopathies including Alzheimer’s disease (AD) are marked by the accumulation of aber-
rantly modified tau proteins. Acetylated tau, in particular, has recently been implicated in
neurodegeneration and cognitive decline. HDAC6 reversibly regulates tau acetylation, but its
role in tauopathy progression remains unclear. Here, we identified an HDAC6-chaperone
complex that targets aberrantly modified tau. HDAC6 not only deacetylates tau but also
suppresses tau hyperphosphorylation within the microtubule-binding region. In neurons and
human AD brain, HDAC6 becomes co-aggregated within focal tau swellings and human AD
neuritic plaques. Using mass spectrometry, we identify a novel HDAC6-regulated tau acet-
ylation site as a disease specific marker for 3R/4R and 3R tauopathies, supporting uniquely
modified tau species in different neurodegenerative disorders. Tau transgenic mice lacking
HDAC6 show reduced survival characterized by accelerated tau pathology and cognitive
decline. We propose that a HDAC6-dependent surveillance mechanism suppresses toxic tau
accumulation, which may protect against the progression of AD and related tauopathies.
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Tau inclusions form the hallmark pathological lesionsobserved in Alzheimer’s disease (AD) and related tauo-pathies. The traditional view of tau pathogenesis has
focused predominantly on hyperphosphorylated tau, but
mounting evidence now implicates aberrant tau acetylation on
lysine residues spanning the microtubule (MT) binding repeat
region (MTBR) as another contributing factor1–4. The sheer
abundance of tau acetylation within the MTBR (>25 lysine resi-
dues identified) and the ability of this modification to control tau
binding to MTs, tau aggregation, and tau oligomer formation
suggest that aberrant tau acetylation acts in a pathological man-
ner to promote neurotoxicity and cognitive decline. Supporting
this notion, recent studies indicate that acetylated tau is also
sufficient to promote synaptic degeneration and cognitive
dysfunction3,5,6.
Analysis of diseased human postmortem brain tissues showed
robust accumulation of acetylated tau within neurofibrillary
tangles (NFTs) and other aggregated tau lesions. For example,
using site-specific tau acetylation antibodies, we and others have
found acetylated tau in AD brains and a range of other tauo-
pathies including Pick’s disease (PiD), corticobasal degeneration
(CBD), and progressive supranuclear palsy (PSP)1,7,8. In contrast
to phosphorylated tau, acetylated tau at residue K280 (ac-K280) is
undetectable in cognitively normal control brains1, suggesting ac-
K280 is a disease-specific marker for tauopathies. This concept
has important clinical implications since acetylated tau could be
directly linked to tauopathy onset, tau strain specificity, and/or
disease progression. Whether or not different tauopathies are
characterized by distinct tau post-translational modification
(PTM) profiles remains unclear. Such a scenario is certainly
plausible given the unique structural, conformational, and seed-
ing properties of tau in AD compared to other tauopathies9–12.
The histone deacetylase (HDAC) family has been implicated in
tau deacetylation1,13. In particular, the deacetylase HDAC6 is
predominantly cytoplasmic, associates with MTs, and reversibly
regulates tubulin acetylation, as well as other cytoplasmic sub-
strates14. Selective HDAC6 inhibition has shown varying degrees
of neuroprotection in some tauopathy or amyloid-beta (Aβ)
plaque models15–19. For example, acute pharmacological HDAC6
inhibition with tubastatin A (TBST) alleviated behavioral and
cognitive deficits in transgenic tau or Aβ mouse models18,19,
spurring significant interest in using HDAC6 inhibitors as AD
therapies. However, we previously showed that acetylated tau is a
substrate for HDAC6 and that inhibition of HDAC6 could result
in elevated levels of acetylated tau1. Thus, chronic long-term
HDAC6 inhibition or depletion could conceivably increase
acetylated tau, promote tau aggregation, and lead to cognitive
defects. Consistent with this possibility, some studies have
reported a neuroprotective role for HDAC6 in protein quality
control (PQC)20–24, including the ability to target misfolded
proteins and damaged organelles for degradation25,26. Interest-
ingly, there are no cognitive abnormalities in HDAC6 KO mice27,
suggesting HDAC6 function is dispensable under normal phy-
siological conditions. However, genetic manipulation of HDAC6
in the context of neurodegenerative tauopathies has not been
examined until this study.
Broad spectrum HDAC inhibitors, including the widely used
pan-HDAC inhibitor trichostatin A (TSA), differentially target
class I (HDAC1/2/3/8), class IIa (HDAC4/5/7/9), class IIb
(HDAC6/10), class III (SIRT1-7), or class IV (HDAC11) HDACs.
Among the pan-HDAC inhibitors, several are FDA-approved and
in various stages of clinical development for the treatment of
neurological conditions as well as cancers (e.g., T-cell lymphoma
and multiple myeloma)28,29. In addition to neurological
applications, HDAC inhibitors are currently being developed
for inflammatory diseases, muscular dystrophies, HIV/AIDS,
and more recently as protective agents against myocardial
infarction30,31. Here, we directly addressed the significance of
HDAC6 in the context of neurodegenerative tauopathies. We
uncovered a novel mechanism through which HDAC6 suppresses
aberrant tau accumulation, highlighting the loss of HDAC6 as a
potential trigger for tau-mediated neurodegeneration.
Results
An HDAC6-chaperone complex targets tau via the MTBR
domain. We analyzed the interaction between full-length wild-
type (WT) human tau and a panel of FLAG-tagged (FL) deace-
tylases, including class I, II, and III HDACs that are reported to
localize and/or shuttle into the cytoplasm (Supplementary Fig. 1a,
b). Co-immunoprecipitation (co-IP) assays revealed robust tau
binding to HDAC3, HDAC6, and SIRT1 (Fig. 1a), but not other
deacetylases including HDAC1, a predominantly nuclear class I
HDAC (Supplementary Fig. 1c). Since HDAC6 bound to lower
molecular weight dephosphorylated tau bands compared to the
other deacetylases, this suggested that HDAC6 may be involved
in the suppression of tau hyperphosphorylation and prompted us
to further evaluate this particular interaction.
To assess the critical domains of HDAC6 that mediate tau
binding, co-IP assays were performed using a panel of HDAC6
mutants lacking catalytic activity at one (H216A or H611A) or
both deacetylase domains (H216/611A), lacking the entire C-
terminus (1–840), lacking the C-terminal polyubiquitin binding
domain (ΔBUZ), or lacking the SE14 domain that mediates
protein–protein interactions (ΔSE14) (Supplementary Fig. 1b).
Neither polyubiquitin binding nor HDAC6 catalytic activity was
required for HDAC6 binding to tau, however, removal of the C-
terminal domain (1–840) or just deletion of the minimal SE14
domain (ΔSE14) significantly reduced tau binding without
affecting total tau levels (Fig. 1b, c and Supplementary Fig. 1d).
These findings suggest that HDAC6 binding to tau is ubiquitin-
independent and mediated, in part, by the SE14 domain.
We also generated a complimentary series of tau deletion
constructs to dissect the regions of tau that are essential for
HDAC6 binding (Supplementary Fig. 1a). Full-length WT human
tau (2N4R) contains two N-terminal repeats and all four MTBR
domains (R1–R4). Repeats R2 and R3 harbor two homologous
hexapeptide motifs known as PHF6* (275VQIINK280) and PHF6
(306VQIVYK311), which are implicated in tau aggregation32,33.
Tau constructs lacking individual repeats or all four repeats
(ΔR1–4) were analyzed by co-IP assays with WT HDAC6
(Fig. 1d). While deletion of R1 and R4 did not impair HDAC6
binding, deletion of R2, and most prominently R3, significantly
reduced binding when compared to full-length WT tau (Fig. 1d,
e). Removal of the entire MTBR domain (ΔR1–4) nearly
eliminated tau-HDAC6 binding (Fig. 1d, e).
Given that six alternatively spliced tau isoforms are expressed
in the adult human brain, we next asked whether HDAC6
preferentially bound 4R-tau isoforms compared to 3R-tau
isoforms that lack R2 due to exon 10 alternative splicing of the
MAPT transcript. HDAC6 binding to 3R-tau isoforms (2N3R,
1N3R, and 0N3R) was slightly reduced when compared to the R2-
containing 4R-tau isoforms (2N4R, 1N4R, and 0N4R) (Fig. 1f, g).
The presence or absence of tau N-terminal inserts did not
appreciably alter tau–HDAC6 binding, further implicating the
MTBR as the critical determinant of the tau–HDAC6 interaction.
Additionally, a panel of frontotemporal dementia (FTD) linked
tau mutations (Supplementary Fig. 1a), many of which cluster in
the R2 and R3 regions, showed a range of binding with some
mutants showing increased HDAC6 binding (e.g., P301L and
S320F) while others showed reduced HDAC6 binding (e.g.,
ΔK280 and L315R) (Fig. 1h, i).
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To further examine the association of tau with HDAC6, we
performed in vitro HDAC6 deacetylase assays reconstituted with
recombinant purified tau and HDAC6 proteins as well as a
fluorescent HDAC reporter. The P301L and S320F tau mutants,
which show enhanced HDAC6 binding, were also more effective
at sequestering and impairing HDAC6 activity while the L315R
mutant, which showed reduced HDAC6 binding, did not
appreciably inhibit HDAC6 activity (Fig. 1j). By extending our
analysis to other HDACs, we found that the enhanced inhibitory
activity of P301L was specific to HDAC6, when compared to
HDAC1 or HDAC3 (Supplementary Fig. 1e). Furthermore, the
HDAC6-binding deficient ΔR1–4 tau mutant (which lacks the
MTBR interacting domain), fully restored HDAC6 activity but
did not restore HDAC1 or HDAC3 activity (Supplementary
Fig. 1e). Thus, binding of the tau R2/R3 aggregate-prone motifs to
HDAC6 is sufficient to impair HDAC6 activity, an effect that is
modulated by the presence of disease-linked familial tau
mutations.
Heat shock proteins (Hsps) including Hsp70 family members


















































































































































































































































































































































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19317-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5522 | https://doi.org/10.1038/s41467-020-19317-4 |www.nature.com/naturecommunications 3
Similarly, HDAC6 interacts with Hsps (e.g., Hsp70 and Hsp90)
as part of a PQC pathway that responds to misfolded and
cytotoxic protein aggregates35–37. Given the shared interaction
with Hsps, we asked whether tau might bind HDAC6 via a
bridged chaperone intermediate by evaluating a tripartite
tau–Hsp–HDAC6 complex. Co-IP assays with individual Hsps
showed that tau exhibited the strongest binding to Hsp70 and
highly related Hsc70, rather than other Hsp family members
including Hsp27 and Hsp90 (Fig. 1k). We note that Hsp70, but
not Hsc70, enhanced tau clearance based on the reduced levels of
total tau observed in the presence of Hsp70 (Fig. 1k, see total tau
input). This finding is consistent with previous reports that
Hsp70 facilitates tau degradation38. Further supporting a
HDAC6–Hsp–tau complex, deletion of the SE14 domain in
HDAC6 similarly reduced the binding of HDAC6 to Hsp70 and
Hsc70 (Supplementary Fig. 1f).
Next, we generated tau mutants that were unable to associate
with Hsc70 by deleting four hydrophobic residues in R2 (I277/
I278) and R3 (I308/V309) known to mediate the tau–Hsc70
interaction34, thereby generating an Hsc70-binding deficient (4Δ)
mutant (Supplementary Fig. 1a). By abolishing the tau–Hsc70
association in the context of full-length WT tau (4Δ), and more
prominently in the context of P301L tau that showed increased
binding to HDAC6 (PL4Δ), we observed a dramatic reduction of
tau–HDAC6 binding (Fig. 1l, m and Supplementary Fig. 1g, h).
We note that phosphorylated tau (AT8 epitope) showed minimal
association with HDAC6 when compared to dephosphorylated
tau (Tau-1 epitope)39 that bound HDAC6 similar to total tau,
suggesting HDAC6 preferentially targets a less phosphorylated
tau species (Fig. 1l).
We also used the acetyltransferase CBP to drive excessive tau
acetylation and observed impaired tau binding to both Hsc70 and
Hsp70, whereas the presence of overexpressed HDAC6 con-
versely promoted tau binding to Hsps (Supplementary Fig. 1i),
suggesting abnormally acetylated tau is sufficient to abrogate
Hsp70/Hsc70 docking onto tau. Overall, our data suggest that the
HDAC6–Hsp complex targets the aggregate-prone tau MTBR as
part of a cellular surveillance mechanism (Fig. 1n).
HDAC6 localizes to sites of aberrant tau accumulation. To
examine tau and HDAC6 localization and their potential coag-
gregation in neurons, dissociated primary cortical neurons from
tau knockout mice (Tau KO) were transfected with P301L Tau-
GFP and HDAC6-FL expression plasmids. Abundant cytoplasmic
colocalization between tau and HDAC6 was observed both in the
soma and along neuritic processes (Fig. 2a and Supplementary
Fig. 2a). We also evaluated the localization of endogenous tau and
HDAC6 in cortical neurons derived from WT and P301S tau
transgenic mice (PS19). Tau and HDAC6 were cytoplasmic in
WT neurons (Fig. 2b and Supplementary Fig. 2b, see top row),
but colocalized within discrete foci, or swellings, that were
deposited along the processes of PS19 neurons (Fig. 2b and
Supplementary Fig. 2b, see bottom row). These Tau-1-
immunoreactive swellings, or varicosities, have been observed in
degenerating axons, in response to neuronal damage, and during
neuroinflammation40.
To further evaluate whether HDAC6 is linked to tau pathology
in human brain, control and AD brain tissues were homogenized,
fractionated, and examined by immunoblotting. In AD brains,
soluble HDAC6 levels were low and accumulated in the insoluble
aggregated fractions, migrating as higher molecular weight
smears of ~150–300 kDa (Fig. 2c, see insoluble HDAC6).
Aggregated HDAC6 tracked with tau NFT pathology, which
was invariably present in all AD brains but not controls (Fig. 2c,
see insoluble p-S202). We also observed reduced soluble
acetylated tubulin, which increased in the insoluble fractions of
AD cases, indicating compromised HDAC6 function (Fig. 2c, see
ac-tubulin). Quantification of immunoblotting confirmed a
solubility shift and inactivation of HDAC6 (Fig. 2d, e). Finally,
HDAC6 associated with Thioflavin S (ThS)-positive neuritic
plaques in human AD cortex by confocal imaging (Fig. 2f). The
plaque-associated pool of HDAC6 co-localized with total tau
(Fig. 2f, TAU-5, see bottom row) and conformational MC1-
positive tau inclusions (Fig. 2f, see top row), an early indicator of
misfolded tau species. These observations suggest that HDAC6
coaggregates with tau and undergoes recruitment into AD lesions.
Pathological tau is acetylated at HDAC6 target sites. We next
sought to identify the major tau PTMs that emerge as a result of
soluble HDAC6 depletion in AD brain. Human AD cortex was
biochemically extracted and soluble tau proteins corresponding to
all six tau isoforms were immunoprecipitated (using a combi-
nation of N-terminal T14 and C-terminal T46 monoclonal tau
antibodies) and analyzed by liquid chromatography and mass
Fig. 1 An HDAC6-chaperone complex targets aberrant tau species. a Co-IP assay evaluating the binding of a panel of human deacetylases to tau in HEK-
293A cells by FLAG (FL) pull-down followed by immunoblotting with a total tau (K9JA) antibody. WT (wild-type) tau preferentially interacts with HDAC3,
HDAC6, and SIRT1 as indicated. b Co-IP assay to determine HDAC6 interacting domains. WT HDAC6, H216/611A (catalytically dead HDAC6 harboring
both H216/H611A mutations), 1–840 (lacking 841–1215), ΔBUZ (lacking 1045–1215), and ΔSE14 (lacking 884–1022) were evaluated. C-terminal mutants
(1–840 and ΔSE14) exhibited decreased binding to tau, as quantified in c. Values are means ± SEM of the ratio of IP total tau to input total tau (background
subtracted and normalized to WT) with unpaired t-test statistical analysis for each HDAC6 mutant compared to WT HDAC6 (CD, *p= 0.0107; 1–840,
**p= 0.0013; ΔBUZ, ns; ΔSE14, **p= 0.0048). d Co-IP assay using tau mutants lacking individual MTBR repeats or the entire MTBR (R1, Q244-K274; R2,
V275-S305; R3, V306-Q336; R4, V337-E372; R1-4, Q244-E372). Removal of R2, R3, or complete removal of the MTBR (R1–4) reduced HDAC6 binding.
The binding of MTBR mutants to HDAC6 were quantified in e (ΔR1, *p= 0.0498; ΔR2, *p= 0.0125; ΔR3, ***p= 0.0002; ΔR4, ns; ΔR1–4, ****p=
<0.0001). f Co-IP assay assessing HDAC6 binding to tau isoforms varying in the number of N-terminal inserts (0N, 1N, or 2N) or MTBR domains (3R or
4R). 3R-tau (0N3R, 1N3R, and 2N3R) and 4R-tau (0N4R, 1N4R, and 2N4R) binding was quantified in g (2N4R vs. 2N3R, *p= 0.0125; 1N4R vs. 1N3R, *p=
0.0435; 0N4R vs. 0N3R, *p= 0.0499). h Co-IP assay assessing HDAC6 binding to FTD disease-causing tau mutations was quantified in i (A125T, ns;
G272V, ns; ΔK280, **p= 0.0069; P301L, ****p < 0.0001; L315R, **p= 0.0029; S320F, **p= 0.0013; V337M, ns; K369I, *p= 0.0384). j HDAC6 activity
assays were used to evaluate the ability of full-length recombinant WT, P301L, L315R, S320F, and ΔR1–4 tau proteins to inhibit HDAC6 activity, which were
normalized to the TSA control. Values are means ± SEM. k Co-IP assay to evaluate tau binding to ectopically over-expressed heat shock proteins (Hsps)
including Hsp27, Hsc70, Hsp70, and Hsp90. Only Hsc70 and Hsp70 bound robustly to tau. l Co-IP assay to evaluate HDAC6 binding to WT and P301L
(PL) compared to their Hsc/Hsp70 binding-deficient mutants (4Δ and PL4Δ; ΔI277/I278/V308/V309). HDAC6 binding was decreased in the presence
of chaperone binding-deficient tau mutations, as quantified in m. n Schematic of the HDAC6-chaperone complex in association with tau. Statistical tests:
p value determined by two-sided unpaired t-test (c, e, g, i, j, m) from n= 3 (e, g, i,), n= 4 (j), and n= 5 (m) biologically independent experiments.
Representative co-IP assays (a, k) are shown from n= 3 biologically independent experiments. Error bars represent means ± SEM (c, e, g, i, j, m). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001. Source data are provided as a Source Data file.
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Fig. 2 HDAC6 co-aggregates with tau and accumulates in pathological tau lesions. a Primary cortical neurons from mouse embryos (E16) of tau
knockout (KO) mice were cultured for 10 days in vitro (10 DIV) and transfected with P301L Tau-GFP (green) and HDAC6-FLAG (FL) (red) expression
constructs followed by imaging. Arrows indicate regions of extensive co-localization along processes. Scale bar= 50 μm. b Primary cortical neurons (E16)
from WT (top) and PS19 tau transgenic (bottom) mice were analyzed by immunofluorescence (IF), detecting co-localized focal swellings of tau (green),
endogenous HDAC6 (red), and the nuclei marked by DAPI (blue). The white rectangle highlights a magnified insert of a neuronal process harboring tau-
positive foci. Scale bar= 50 μm. c Biochemical fractionation of soluble high-salt fractions and insoluble urea fractions were extracted from frontal cortex of
control and AD brains followed by immunoblotting to detect HDAC6, tau, Hsc70, and acetylated tubulin. The arrows highlight acetylated tubulin fragments
~37 kDa and higher molecular weight species ~150 kDa. d, e Immunoblotting results were quantified by densitometry. f AD cortical sections were analyzed
by double-labeling IF using either conformational tau (MC1) or total tau (TAU-5) antibodies (blue), combined with Thioflavin S (ThS) (green), and HDAC6
(red) to evaluate localization in proximity to AD neuritic plaques. White arrows highlight regions of tau and HDAC6 immunoreactivity that are associated
with ThS positive plaques. Scale bar= 50 μm. Statistical tests: p value determined by two-sided unpaired t-test with Welch’s correction from n= 5
biologically independent samples (d, e). Representative neurons are shown from n= 3 biologically independent experiments (a, b) and n= 3 independent
AD brains (f). Error bars represent means ± SEM and are plotted relative to control (d) or relative to AD (e). *p < 0.05, **p < 0.01, ***p < 0.001. Source data
are provided as a Source Data file.
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spectrometry (LC/MS–MS). As shown in Table 1, many tau
PTMs were identified in AD brains including phosphorylation at
N-terminal, mid-domain, and C-terminal residues. Immunopre-
cipitated soluble tau contained three acetylation sites at tau
residues K259, K311, and K385 (Table 1). Acetylation at residue
K311 was of primary interest for the following reasons. K311
resides in R3 of the MTBR, a region that physically binds
HDAC6 (Fig. 1d, e). In addition, R3 contains the PHF6 hex-
apeptide motif (306VQIVYK311) known to mediate tau aggrega-
tion33, which is homologous to the R2-containing PHF6* motif
(275VQIINK280) that is subject to acetylation at the correspond-
ing K280 residue leading to tau dissociation from MTs and
enhanced aggregation1,41.
We hypothesized that tau acetylation at the K311 residue might
contribute to tau aggregation, given its central location in the
PHF6 motif that mediates tau aggregation. To test this possibility
in vitro, we purified recombinant tau proteins (K18 tau contain-
ing only the MTBR) and inserted either acetylation-mimic (K →
Q) or deacetylation-mimic (K → R) mutations at K311 for
subsequent aggregation and oligomerization assays (Supplemen-
tary Fig. 3). K311Q showed accelerated aggregation kinetics and
completely transitioned from the soluble supernatant fraction
(Sup) to the aggregated pellet fraction (Pel) by 1 h, an effect that
was comparable to the FTD disease-linked P301L mutant
(Supplementary Fig. 3a). Aggregated K311Q was also character-
ized by dimers and trimers ~30 and 45 kDa, suggestive of higher
order multimeric tau species. In contrast, the K311R
deacetylation-mimic showed delayed aggregation kinetics and
did not achieve complete aggregation until 8 h similar to WT tau.
These results were also quantified by Thioflavin T (ThT)
fluorescence, which showed a rapid increase in K311Q aggrega-
tion leading to ~3-fold increase in ThT-positive fibrils by 8 h
compared to WT or K311R mutant tau (Supplementary Fig. 3b).
Using dynamic light scattering, we further confirmed the
presence of tau oligomers (Supplementary Fig. 3c). Only
K311Q and P301L formed higher order structures as early as
15 min, which gradually progressed in intensity until 1 h, at which
point tau fully aggregated, in contrast to WT or K311R mutant.
Therefore, mimicking acetylation at only a single residue (K311),
in the absence of other tau modifications, was sufficient to
accelerate tau oligomerization and aggregation.
To begin characterizing tau acetylation at residue K311 in the
brain, we generated acetylation site-specific K311 polyclonal
antibodies (hereafter referred to as ac-K311). One of the four
purified antibodies (ac-K311, #5089) showed high specificity and
sensitivity for acetylated tau, but not unmodified tau (Supple-
mentary Fig. 4a, b). The specificity was demonstrated by minimal
detection of an acetylation-deficient K311R mutation, suggesting
the immunoreactivity is directed primarily towards acetylation of
the K311 residue (Supplementary Fig. 4b). Ac-K311 did not
distinguish among tau isoforms in vitro, as CBP-mediated
acetylation of all six tau isoforms was observed in cultured
HEK-293A cells (Supplementary Fig. 4c). The highest specificity
clone (#5089) was subsequently employed for the analysis of AD
and related tauopathy cases.
Immunoblotting of AD brain homogenates with ac-K311
detected robust insoluble aggregated high molecular weight tau
species, similar to mature tau pathology detected with total tau
antibodies (Fig. 3a, b). Consistent with ac-K311 labeling tau
pathology, immunohistochemistry (IHC) analysis detected wide-
spread neuropil thread and NFT pathology in all AD brains
analyzed, but not healthy control brains (Fig. 3c and Supple-
mentary Fig. 5a). While 3R-tau predominant Pick’s disease (PiD)
was also strongly immunoreactive (Fig. 3c, see ac-K311 positive
Pick bodies), surprisingly, 4R-tau predominant corticobasal
degeneration (CBD) and progressive supranuclear palsy (PSP)
showed minimal ac-K311 immunoreactivity (Fig. 3c, see ac-K311
negative CBD and PSP cases), despite the presence of phos-
phorylated tau inclusions in all tauopathy cases analyzed
(Supplementary Fig. 5b). The lack of ac-K311 pathology in
CBD and PSP brain was unexpected since residue K311 is present
in all six tau isoforms (both 3R-tau and 4R-tau) that form
inclusions in AD (mixed 3R/4R tau pathology), PiD (3R tau
pathology), and CBD/PSP (4R tau pathology). To confirm these
findings, double-labeling immunofluorescence showed colocali-
zation of ac-K31l with 3R-tau inclusions in AD and PiD (Fig. 3d).
In AD brains, ac-K311 labeled 3R-tau pathology more robustly
than 4R-tau pathology based on prominent colocalization with
the 3R-tau specific antibody RD3 (Fig. 3d, compare top row
AD–RD3 with AD–RD4). Similar to the IHC analysis, neuronal
and glial pathology in CBD (astrocytic plaques) and PSP (globose
tangles and tufted astrocytes) were largely undetected by ac-K311
(Fig. 3d, see negative ac-K311 immunoreactivity in CBD and PSP
cases). To further confirm disease-specificity, we screened an
additional 42 CBD/PSP cases and found only four cases with rare
ac-K311 immunoreactivity that was in the form of AD-like
neuritic plaques and neuronal tangles that were both RD3 and
RD4 positive, suggesting ac-K311 immunoreactivity predomi-
nantly occurs in 3R-tauopathies (Supplementary Table 1).
These observations were further evaluated by immunoblotting
purified PHF-tau preparations isolated from a panel of tauopathy
brains42. Detection of ac-K311 tau bands were observed in AD,
and more prominently in PiD, migrating at ~60–65 kDa (bands
labeled #3 and #5), but were not present in CBD or PSP brains
(Fig. 3e). The ac-K311 bands were immunoreactive with the RD3
antibody, supporting the notion that ac-K311 preferentially
detects 3R-tau. Consistent with the 3R-tau specificity, we
evaluated ac-K311 immunoreactivity in cortical sections from a
human FTLD-tau P301L case harboring predominantly 4R-tau





p-S46 45ESPLQTPTEDGSEEPGSETSDAK67 15.13 1.0
p-T50 45ESPLQTPTEDGSEEPGSETSDAK67 43.49 −1.2
p-T175 171IPAKTPPAPK180 53.71 −0.3
p-T181 175TPPAPKTPPSSGEPPK190 60.80 −0.6
p-S184 175TPPAPKTPPSSGEPPK180 21.79 −3.1
p-S198 195SGYSSPGSPGTPGSR209 53.54 0.2
p-S199 195SGYSSPGSPGTPGSR209 53.91 −1.1
p-S202 195SGYSSPGSPGTPGSR209 44.83 0.1
p-S210 210SRTPSLPTPPTR221 19.07 0.2
p-T212 212TPSLPTPPTREPK224 34.30 −0.3
p-S214 210SRTPSLPTPPTR221 52.35 −0.5
p-T217 212TPSLPTPPTREPK224 42.92 0.4
p-T231 226VAVVRTPPKSPSSAK240 40.57 0.7
p-S235 225KVAVVRTPPKSPSSAK240 28.16 0.1
p-S237 226VAVVRTPPKSPSSAK240 43.63 0.3
p-S238 226VAVVRTPPKSPSSAK240 34.65 0.2
ac-K259 258SKIGSTENLK267 15.79 −0.1
p-S262 260IGSTENLKHQPGGGK274 29.82 −0.5
ac-K311 306VQIVYKPVDLSK317 39.04 0.0
ac-K385 384AKTDHGAEIVYK395 46.13 0.6
p-S396 386TDHGAEIVYKSPVVSGDTSPR406 48.12 0.0
p-T403 386TDHGAEIVYKSPVVSGDTSPR406 54.50 0.1
p-S404 396SPVVSGDTSPR406 57.89 −0.7
Tau proteins were isolated from AD brain extracts and purified for LC-MS/MS analysis to
identify sites of tau phosphorylation and acetylation. The residue number, peptide sequence
(bold denotes the modified residue), and significance values are depicted. The tau sequences
listed are based on full-length human 2N4R tau (441 residues). The protein confidence score p is
represented as −10Log p. Peptide mass accuracy is represented as parts per million (ppm).
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Fig. 3 AD and related tauopathies present with distinct tau acetylation profiles. a Immunoblotting of control and AD brains homogenates using
antibodies to detect ac-K311, total tau (TAU-5), and GAPDH. b Immunoblots from a were quantified and normalized to control (soluble) or AD (insoluble)
samples. c Immunohistochemistry (IHC) analysis using ac-K311 (#5089) in a panel of 3R and 4R tauopathies: Alzheimer’s disease (AD), Pick’s disease
(PiD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP). Only 3R-tauopathies (AD and PiD) demonstrated ac-K311-
immunoreactive pathological lesions. Scale bar= 50 μm. d Double-labeling IF to mark ac-K311 (red) in combination with tau-isoform specific antibodies.
The green channel represents 4R-tau (RD4) in AD, CBD, and PSP or 3R-tau (RD3) in AD and PiD. Ac-K311 colocalized strongly to 3R-tau pathology in AD
and PiD. Scale bar= 50 μm. e Immunoblotting of isolated PHF-tau from the indicated tauopathies probed with ac-K311, 3R-tau (RD3), 4R-tau (RD4), and
total tau (K9JA) antibodies. The arrows highlighting tau bands 1–5 represent distinctly migrating tau bands that are resolved by immunoblotting. Statistical
tests: p value determined by unpaired t-test with Welch’s correction from n= 5 independent samples (b). Representative images are shown from n= 10 (c,
d) and n= 2 (e) independent samples. Error bars represent means ± SEM. *p < 0.05 and **p < 0.01. Source data are provided as a Source Data file.
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pathology, which also showed minimal ac-K311 immunoreactiv-
ity (Supplementary Fig. 5c). The lack of ac-K311 immunor-
eactivity in 4R tauopathies compared to 3R tauopathies implies
the existence of a unique tau profile, tau conformation, and/or tau
strain that distinguishes 3R from 4R tauopathies. While ac-K311
showed specificity for 3R-tau in diseased human tauopathy
brains, we note that this was not observed in vitro, as both 3R-tau
and 4R-tau isoforms showed identical patterns of acetylation
mediated by CBP in cultured cells (Supplementary Fig. 4c).
Therefore, all tau isoforms have the potential to be acetylated at
K311 in vitro, however in human tauopathy brains, K311
acetylation emerges in a disease and tau isoform-specific pattern.
We next examined whether HDAC6 is sufficient to target and
repair aberrant tau PTMs. CBP-acetylated tau was potently
deacetylated by HDAC6 using site-specific ac-K280 and ac-K311
antibodies (Fig. 4a, b). Further analysis with a panel of
phosphorylated tau antibodies showed that CBP-mediated tau
acetylation also led to increased tau phosphorylation at S262 and
S356 (MARK2-dependent target KXGS motifs) as well as S202
































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 The targeting of tau by HDAC6 is regulated by tau kinases. a Immunoblotting of HEK-293A cells cotransfected for 48 h with WT tau, the
acetyltransferase CBP, and WT HDAC6 (where indicated) using acetylation or phosphorylation specific tau antibodies. b–d The relative levels of modified
tau within the MTBR (ac-280, ac-K311, p-S262, and p-S356) or outside the MTBR (AT8, p-S202, p-T205, and p-S396) were quantified by densitometry
of tau PTMs normalized to total tau (Tau 12). e Cells expressing the indicated tau constructs (WT, 4Δ, PL, and PL4Δ) were treated with tubastatin A
(TBST) to inhibit HDAC6 or cotransfected with WT HDAC6 to suppress tau acetylation followed by immunoblotting with acetylation or phosphorylation
specific tau antibodies as in a. f–l Primary cortical neurons (E16) from PS19 derived tau-transgenic mice cultured for ten DIV were treated overnight with
TBST at a concentration of 1–5 μM and analyzed by immunoblotting followed by quantification by densitometry of tau PTMs normalized to human, mouse,
or total tau (K9JA). The arrows in f highlight overexpressed human tau migrating at ~65 kDa compared to mouse tau at ~50 kDa (see also Supplementary
Fig. 6c to distinguish between human and mouse tau). m Co-IP assay evaluating HDAC6 binding to WT tau, tau-P301L, and tau-P301L/4SE mutant
containing S→ E substitutions at all four MARK2-targeted phosphorylation sites (S262/S290/S324/S356E). Despite P301L tau showing greater binding to
HDAC6, the addition of the MARK2 phosphorylation-mimic mutations reduced HDAC6 binding. n Co-IP assay evaluating tau-P301L mutant tau binding to
HDAC6 in the presence of MARK2 or GSK-3β kinases. o HEK-293A cells co-transfected with WT tau, MARK2, or GSK-3β (where indicated) were analyzed
by immunoblotting using acetylation or phosphorylation specific tau antibodies followed by quantification of ac-K311 and ac-Tubulin levels normalized to
GAPDH levels in p. q HEK-293A cells co-transfected with WT and MARK2 were treated with a panel of HDAC inhibitors including tubastatin A (TBST,
HDAC6 inhibitor, 5 μM), trichostatin A (TSA, class I/II HDAC inhibitor, 1 μM) or nicotinamide (NCA, class III HDAC inhibitor, 5 mM) and analyzed as
described in o. Statistical tests: p value determined by two-sided unpaired t-test from n= 6 (b–d), n= 3 (g–l), and n= 4 (p) biologically independent
experiments. Error bars represent means ± SEM (b–d, g–l, p). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Source data are provided as a Source
Data file.
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(AT8 and T205) or C-terminal (S396) regions (Fig. 4a–d).
Surprisingly, HDAC6 not only reduced acetylation but also
reduced tau phosphorylation exclusively at MARK2 target sites
S262 and S356 (Fig. 4a–d). To evaluate which HDAC6 catalytic
domain (CD1 or CD2) is responsible for tau deacetylation, we
analyzed mutations in CD1 (H216A) or CD2 (H611A) and found
that inactivation of CD2 is sufficient to restore CBP-mediated tau
acetylation, which suggests that HDAC6 catalytic activity towards
tau substrates resides in the CD2 domain (Supplementary
Fig. 6a).
We examined whether HDAC6 inhibition conversely promoted
S262/S356 phosphorylation within the MTBR. Indeed, either
abrogation of the tau–HDAC6 interaction using the 4Δ mutations
(which reduces tau–HDAC6 binding) or pharmacological inhibition
of HDAC6 activity using tubastatin A (TBST), were sufficient to
increase phosphorylation in the MTBR with less prominent effects
on nonMTBR tau phosphorylation sites (e.g., S202 and S396)
(Fig. 4e). Furthermore, ectopic overexpression of HDAC6 reduced
S262/S356 phosphorylation, even in the presence of the PL4Δ
mutant that was susceptible to hyperphosphorylation (Fig. 4e).
Surprisingly, tau mutants that are HDAC6 binding-deficient (either
4Δ or PL4Δ) showed less ac-K311 signal (Fig. 4e and Supplementary
Fig. 6b). The reduced acetylation may potentially be due to other
unrelated HDACs targeting tau, since trichostatin A (TSA), a pan-
HDAC inhibitor, restored the acetylation of the 4Δ mutant back to
WT levels (Supplementary Fig. 6b). In contrast, inhibiting class III
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To determine whether HDAC6 inhibition affects tau PTMs in
neurons, we exposed PS19 cultured primary neurons to
increasing concentrations (1–5 μM) of TBST (Fig. 4f). Similar
to the HEK-293A cell-based results, TBST treatment led to an
increase in S262 and S202 phosphorylation in PS19 neurons, but
not S396 phosphorylation (Fig. 4f–i). We also analyzed both
human transgenic tau and endogenous mouse tau to distinguish
among the total tau species (Fig. 4j, k and Supplementary Fig. 6c).
The human transgenic P301S mutant tau was more susceptible to
S262 phosphorylation (~2-fold) in response to HDAC6 inhibi-
tion, as endogenous mouse tau was not as readily hyperpho-
sphorylated (Fig. 4f, g). While HDAC6 inhibition increased the
levels of acetylated tubulin as expected (Fig. 4l), HDAC6
inhibition is not sufficient on its own to generate acetylated tau
at residues K280 or K311 in primary neurons lacking mature tau
pathology. Active tau acetyltransferases (e.g., CBP/p300) may be
required to promote acetylated tau levels to the extent observed in
human tauopathies1,43.
Given the potential interplay between tau phosphorylation and
acetylation in the MTBR, we examined the impact of MARK2-
mediated tau phosphorylation within the MTBR. We found that a
tau phosphorylation-mimic containing four S → E substitutions
at MARK2 phosphorylation sites (S262/S290/S324/S356E)
reduced tau binding to HDAC6 (Fig. 4m). We next generated a
constitutively active MARK2 construct (MARK2–T280E), which
led to tau hyperphosphorylation at MARK2-target sites (S262/
S356) and a striking dissociation of tau from HDAC6 (Fig. 4n).
The abrogation of tau-HDAC6 binding was specific to MARK2,
as the dissociation was not observed with GSK3β, a kinase that
does not phosphorylate tau in the MTBR (Fig. 4n). MARK2-
mediated tau phosphorylation not only led to the dissociation of
the tau–HDAC6 complex, but also reduced tau and tubulin
acetylation (Fig. 4o, p). Therefore, dissociation of tau from
HDAC6 via tau kinase activation or by employing tau mutants,
that abrogate HDAC6 binding (e.g., 4Δ) reduced the acetylation
of tau (Fig. 4q and Supplementary Fig. 6b). This could again
reflect the targeting of tau by other HDACs in a compensatory
manner, since the MARK2-mediated tau deacetylation was TSA-
sensitive (Fig. 4q). In contrast, we note that GSK3β, which
promotes tau phosphorylation in regions flanking the MTBR,
increased tau acetylation within the MTBR (Fig. 4o, p). Overall,
our data suggest that tau kinases modulate the ability of HDAC6
to target and alter tau PTMs.
Loss of HDAC6 accelerates tauopathy in mice. In contrast to
alleviating tauopathy progression, our results to this point suggest
that HDAC6 depletion might enhance pathological tau and
accelerate tauopathy in vivo. To directly test this hypothesis, we
crossed P301S tau transgenic mice (PS19) to HDAC6 KO mice,
thereby generating PS19 × HDAC6 KO mice (referred to here-
after as PHK mice). We chose the PS19 model since this line
reliably recapitulates many hallmarks of tauopathy including
robust tau pathology, cognitive dysfunction, and decreased sur-
vival44. We note that HDAC6 KO mice are breeding-competent,
show no developmental or neurodegenerative phenotypes, live a
normal lifespan, and show no tau pathology (Supplementary
Fig. 7)27,45. The Kaplan–Meier survival curve showed the
expected PS19 mortality rates similar to that previously reported
(~50% survival by 12 months) (Fig. 5a, red line). The PHK mice
showed accelerated mortality as early as 4 months old with sig-
nificantly reduced survival at end stage (Fig. 5a, purple line). The
reduced survival of PHK mice correlated with progressive loss in
body weight (Fig. 5b).
To assess cognitive function, mice were evaluated in the Morris
water maze for acquisition and strength of spatial learning. To
exclude potential differences in motor function in tauopathy
mice, we evaluated swim speed and observed no differences
among all genotypes (Fig. 5c). During the hidden platform test,
WT, HDAC6 KO, and PS19 mice showed significantly decreased
latencies across the training period, while the PHK mice showed
poor learning during the entire 9-day regimen (Fig. 5d). In a
probe trial without the platform, only the WT and HDAC6 KO
mice showed a preference for the correct quadrant (Fig. 5e, within
genotype comparisons are denoted by #). Notably, a trend for
quadrant preference was observed in the PS19 mice (p= 0.0894).
In contrast, PHK mice failed to demonstrate any selectivity for
the target quadrant and spent significantly more time than the
other genotypes in the incorrect quadrant (Fig. 5e, purple). When
swim path crosses were measured, the PHK mice also exhibited
significantly fewer crosses over the target area, and more crosses
over the incorrect location, in comparison to both WT and
HDAC6 KO (Fig. 5f). Neither the PS19 or PHK mice had
preference for crossing the target area, in contrast to WT and
HDAC6 KO mice. Overall, the behavioral analysis suggests that
PHK mice do not show acquisition of spatial learning, indicating
that loss of HDAC6 exacerbates hippocampal-dependent cogni-
tive decline in a mouse tauopathy model.
Fig. 5 HDAC6 depletion in tauopathy mice reduces survival and accelerates cognitive decline. a Survival analysis showed a significantly reduced survival
rate in PS19 tau transgenic mice with HDAC6 deletion (PHK). Two-sided log-rank (Mantel-Cox) test with multiple comparisons was performed to assess
significance among genotypes (WT, black squares, n= 22; HDAC6 KO, blue circles, n= 42; PS19, red triangles, n= 27; PHK, purple diamonds, n= 37)
(*p < 0.05, ****p < 0.0001). b Decreased body weights in PS19 and PHK mice were observed at 32 weeks and 37 weeks of age (WT, n= 11; HDAC6 KO,
n= 15; PS19, n= 15; PHK, n= 13). Comparisons among genotypes were as follows: *p < 0.05, **p < 0.01, ***p < 0.001, comparison to same measure in WT;
ΔΔ, p < 0.01, ΔΔΔ, p < 0.001, comparison to HDAC6 KO. c No genotype differences were observed in average swimming speed across 9 days of training.
d Acquisition of spatial learning using Morris water maze was evaluated for all genotypes (7–8-month old male mice). Data are means ± SEM from four
trials per day. PHK mice showed impaired learning. p-values represent within-genotype repeated measures ANOVAs, effect of training day. WT,
****p < 0.0001; HDAC6 KO, ****p < 0.0001; PS19, **p= 0.0052; PHK, p= 0.4251. Asterisks represent comparisons to WT. e Quadrant preference data are
means ± SEM from a 1-min probe trail without the platform following hidden platform training. Target indicates the quadrant where the platform had been
placed during training, versus the opposite quadrant. Brackets signify within-genotype comparisons, effect of quadrant (#p < 0.05; ###p < 0.001; ns not
significant). Comparisons among genotypes were as follows: **p < 0.01, ***p < 0.001, comparison to same measure in WT; ΔΔΔ, p < 0.001, comparison to
HDAC6 KO; ϕϕ, p < 0.01 comparison to PS19. f Swim path crosses during a 1 min probe trial without the platform following hidden platform training. Target
indicates the location where the platform had been placed during training, versus the corresponding location in the opposite quadrant. Within-genotype
comparisons were used to determine effect of quadrant (##p < 0.01; ns not significant). Comparisons among genotypes were as follows: *p < 0.05,
**p < 0.01, comparison to same measure in WT; Δ, p < 0.05, comparison to HDAC6 KO. Statistical tests: p value determined by repeated measure
ANOVAs followed by Fisher’s protected least-significant difference (PLSD) posthoc test from WT (n= 11), HDAC6 KO (n= 16), PS19 (n= 15), and PHK
(n= 13) mice (c–f). All error bars throughout this figure represent means ± SEM (b–f). Source data are provided as a Source Data file.
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To evaluate the differential effects of HDAC6 depletion in the
setting of Aβ plaques rather than tau pathology, we generated
plaque-bearing mice lacking HDAC6 using the 5xFAD model of
Aβ deposition (5xFAD × HDAC6 KO mice referred to hereafter
as 5xFHK mice). Indeed, depletion of HDAC6 in the 5xFAD mice
rescued the loss in body weight and spatial learning defects
observed in 5xFAD mice (Supplementary Fig. 8), which is
consistent with the previously reported cognitive improvements
observed in APPPS1 mice upon HDAC6 depletion27. These
results support the notion that HDAC6 loss has opposing effects
depending on the nature of the pathology.
Given the cognitive defects in the tauopathy model, we next
asked whether tau pathology was accelerated in PHK mice when
compared to PS19 littermate controls. We evaluated pathological
tau in the cortex and hippocampus by IHC analysis using the MC1
and AT8 antibodies, as well as Thioflavin S (ThS) fluorescence to
evaluate the extent of mature tau amyloid structure46,47 (Fig. 6a, d).
While total tau and phosphorylated tau immunoreactivity were
comparable (Fig. 6b, c), PHK mice accumulated more MC1-
immunoreactive tau in the soma and neurites of both the cortex
and hippocampus (Fig. 6a, e). Consistent with the increased MC1
immunoreactivity, PHK mice also harbored more cortical ThS-
positive tau inclusions when compared to PS19 mice (Fig. 6d, e and
Supplementary Fig. 9a), indicating that loss of HDAC6 increases
aggregate-prone tau species. Finally, we quantified hippocampal
area as an indicator for neurodegeneration and observed a
significant reduction in total area of the hippocampus, dentate
granule layer, and CA regions in PHK mice compared to PS19 mice
(Fig. 6f and Supplementary Fig. 9b).
Immunoblotting of mouse brain homogenates further showed
that PS19 mice have minimal acetylated tau, while PHK mice
lacking HDAC6 had elevated acetylated tau at multiple residues
(K280 and K311) in parallel with increased tau phosphorylation
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Fig. 6 HDAC6 depletion accelerates tau pathology and neurodegeneration. Representative IHC images of pathological tau detected with the MC1 (a),
phosphorylated tau (AT8) (b), and total tau (Tau 12) (c) antibodies in the cortex (top panels) and hippocampus (bottom panels) of 12-month old WT,
PS19, and PHK mice. Representative images are shown from n= 3 mice per genotype. Scale bar= 50 μm (a–c, scale bar is identical for both hippocampus
and cortex). d ThS-positive tau pathology (green) is double-labeled with total tau (TAUY9, red) and DAPI (blue) to highlight cortical amyloid burden. The
high magnification inset depicts a neuron with robust tau pathology. e Quantification of MC1 and AT8 immunoreactivity in the hippocampus and ThS-
positive inclusions in the cortex (n= 3 mice per genotype). Error bars represent means ± SEM. Statistical analysis was performed using two-sided unpaired
t-test and normalized to PHK. f Quantification of hippocampal area using total hippocampus, dentate gyrus, and CA brain area from 12-month-old mice
(n= 4 mice per genotype). Measurements were performed in an unbiased manner using ImageJ software. Statistical tests: one-way ANOVAs were
performed with Tukey’s test for multiple comparisons among groups. Data shown represent means ± SEM normalized to WT. *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19317-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5522 | https://doi.org/10.1038/s41467-020-19317-4 |www.nature.com/naturecommunications 11
MTBR (AT8, S202, and S396) (Fig. 7a, b). In addition, pathological
cleaved tau (detected by the TauC3 antibody) and tau oligomers
(detected by the TOC1 oligomer-specific antibody) were also
increased in PHK mice, supporting the notion that HDAC6
depletion generates a variety of pathological tau conformers
(Fig. 7a–d). Lastly, consistent with tau-mediated neurotoxicity, the
accelerated accumulation of tau pathology in PHK mice reduced
postsynaptic (PSD-95), but not presynaptic (synaptophysin),
markers (Fig. 7e). Quantification of the molecular changes in
PHK mice is depicted in Fig. 7f–i, which strongly supports loss of
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Discussion
In this study, we evaluated HDAC6 as a mediator of tau patho-
genesis. Contrary to the notion that HDAC6 depletion alleviates
neurodegeneration, our results suggest that HDAC6 acts in a
protective capacity under conditions of tauopathy to suppress
aberrant tau accumulation, and that sustained or chronic loss of
HDAC6 results in accelerated tau pathology, cognitive dysfunc-
tion, and reduced survival. Overall, our data warrant a careful
evaluation of whether targeting, depleting, or inactivating
HDAC6 will provide therapeutic utility in either AD or other
tauopathy patients. A more thorough analysis of the impact of
HDAC depletion or inactivation in the brain is needed, including
the cell-type specific implications of manipulating HDAC6, as
well as clinical assessments at varying stages of disease
progression.
Our prior study indicated that tau is a major target of HDAC6,
as HDAC6 efficiently deacetylated tau in vitro and in cell-based
assays1. We now demonstrate significantly increased acetylated
tau in tauopathy mice lacking HDAC6, further validating
HDAC6 as a bona fide tau deacetylase in vivo. Since soluble
functional HDAC6 was depleted and co-aggregated with tau in
AD brain, we speculate that gradual loss of HDAC6 function
contributes to the accumulation of acetylated tau that we and
others have commonly observed in AD brains, hence early
changes in HDAC6 localization or activity may represent a
pathological event that precedes tau pathogenesis. We note that
HDAC3 and SIRT1 have also been implicated as deacetylases that
regulate tau deacetylation (Fig. 1a)13,48, suggesting potential
synergy between HDAC6 and other deacetylases towards tau.
Further analysis of mice lacking multiple deacetylases could
address overlapping or compensatory roles for multiple HDACs
in suppressing tau pathology.
While acute HDAC6 inhibition may be protective in the
absence of tau pathology18, our data in mouse and human brain
suggest that chronic and/or sustained HDAC6 depletion may
exacerbate any existing tauopathy leading to synaptic and cog-
nitive defects. Furthermore, our data potentially reconcile a long-
standing controversy as to whether loss of HDAC6 is beneficial or
detrimental, as HDAC6 loss exacerbated disease progression in a
tauopathy model (Fig. 5) but restored cognition in a model of Aβ
plaque deposition (Supplementary Fig. 8). Thus, the specific
nature of the pathology that emerges in the diseased brain may
dictate whether HDAC6 is required. Loss or inhibition of HDAC6
may be neuroprotective under conditions in which tau pathology
is absent, or at least below a particular threshold. Indeed, we
previously showed that HDAC6 inhibition during an Aβ-induced
neuroinflammatory challenge can suppress neuronal damage40.
In the absence of robust tau pathology, tau is mostly bound to
MTs49 and not appreciably acetylated at most lysine residues1,43.
Therefore, we suspect that HDAC6 inhibition under conditions
lacking robust tau pathology might alter the acetylation status of
non-tau HDAC6-dependent substrates (e.g., tubulin, cortactin,
Hsp90) and thus restore axonal transport and MT-dependent
trafficking, for example in the presence of Aβ (as we observed in
the 5xFAD model)50. Indeed, loss or inhibition of HDAC6 was
reported to stabilize MTs and improve axonal transport in non-
tauopathy syndromes including Charcot Marie Tooth (CMT)
neuropathy51,52, amyotrophic lateral sclerosis (ALS)53, Rett syn-
drome54, and Aβ plaque deposition19.
In contrast, under conditions in which aberrant tau accumu-
lates in the cytosol, either due to genetic mutations or other
potential pathological triggers (e.g., MT dysfunction), HDAC6
activity may be required to bind tau via the aggregate-prone R2/
R3 motifs and suppress aberrant tau PTMs that would otherwise
generate toxic tau species. We propose that tau aggregation may
in turn promote HDAC6 coaggregation and inactivation of its
catalytic activity, which would further amplify this cycle and lead
to robust acetylated tau accumulation, as we and others com-
monly observe in AD brains. In addition to tau, HDAC6 rever-
sibly regulates components of the actin remodeling machinery
(e.g., actin and cortactin)55, a variety of MT-associated factors
(e.g., tau, MAP2, and MAP4)56, heat shock signaling (e.g., Hsp70
and Hsp90)36,57, and more recently, stress granule (SG) forma-
tion by controlling liquid–liquid phase separation (LLPS)58.
Therefore, HDAC6 inhibition could conceivably increase neuro-
nal vulnerability by influencing tau processing as well as the stress
response, mitophagy, autophagosome–lysosome fusion, and
cytoskeletal remodeling. Future efforts are needed to more clearly
determine the impact of HDAC6 inhibition on tau pathology,
particularly at early versus late stages of tauopathy progression.
Using a panel of FTD-associated tau mutants, HDAC6 showed
increased binding to P301L and S320F mutations. The exact
properties of these particular mutants that enable more robust
engagement with HDAC6 is not clear, however a recent study
indicated synergistic aggregation and seeding of the P301L and
S320F mutations59–61. Our data suggest that HDAC6 may pre-
ferentially target specific aggregate-prone conformations, or
strains, via a chaperone bridge, as mutations that abrogate
tau–chaperone binding also diminished tau–HDAC6 binding
(Fig. 1l–n). The Hsc70/Hsp70 sensor appears to detect the R2/R3
motifs within the MTBR, thus recruiting and enabling HDAC6 to
target particular tau species. How HDAC6 might also suppress
tau phosphorylation at KXGS motifs is unclear, but this could
involve a complex interplay between different tau remodeling
complexes (e.g., tau targeted HDACs and kinases) and synergy
amongst various tau PTMs. One intriguing possibility is that
specific tau acetylation patterns prime phosphorylation within the
MTBR, and therefore HDAC6-mediated deacetylation could
effectively shift the equilibrium towards a less phosphorylated
and presumably less toxic state. Indeed, a complex interplay
among tau PTMs (e.g., acetylation and phosphorylation) within
the MTBR was recently suggested62. Our data are consistent with
specific priming events that establish a unique tau PTM profile, or
signature, that results in tau-mediated toxicity.
Fig. 7 HDAC6 depletion accelerates tau pathology and causes synaptic dysfunction. a Immunoblotting of soluble high salt fractions from 12-month-old
WT, PS19, and PHK cortex to evaluate the following: acetylated tau (ac-K280 and ac-K311), phosphorylated tau in the MTBR (p-S262 and p-S356),
nonMTBR phosphorylated tau (AT8, p-S202, and p-S396), cleaved tau (TauC3), endogenous mouse tau (TAU-5, ~50 kDa), human tau (TAU-5 and Tau 12,
~65 kDa), HDAC6, and the HDAC6 substrate ac-tubulin. b Similar immunoblotting as in a was performed using insoluble SDS fractions. Acetylated tau (ac-
K280 and ac-K311), phosphorylated tau in the MTBR (p-S262) and total tau (TAU-5) were detected in the insoluble fractions. c, d Dot blot analysis was
used to detect oligomeric tau in soluble (c) and insoluble (d) fractions with the TOC1 antibody. e Synaptic markers including postsynaptic (PSD-95),
NMDA receptors (p-NR2B and total NR2B), and presynaptic (Synaptophysin) were evaluated by immunoblotting. f–i Quantification of acetylated tau (f),
conformational tau (g), phosphorylated tau (h), and synaptic markers (i) were determined by densitometry and values were normalized relative to PHK
mice (f–h) or WT mice (i). Statistical tests: one-way ANOVAs were performed (p-values are listed above graphs) and Tukey’s multiple comparison tests
were used to compare among groups. Representative immunoblotting data are shown from n= 3 biologically independent samples (a–e). Error bars
represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not significant. Source data are provided as a Source Data file.
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Tau acetylation may facilitate the formation of toxic tau oli-
gomers that lead to synaptic dysfunction. A K174Q acetylation-
mimic mutant showed impaired tau turnover and induced cog-
nitive deficits3. Similarly, K274/K281Q acetylation mimic trans-
genic mice showed altered levels of critical synaptic factors (e.g.,
KIBRA), altered postsynaptic remodeling, and impaired long-
term potentiation leading to memory deficits6. Here, we observed
that loss of HDAC6 similarly led to increased tau oligomers and
correlated with reduced postsynaptic integrity (Fig. 7). Given the
possibility that distinct prion-like tau strains could emerge under
different clinical tauopathy settings, we propose that acetylated
tau might contribute to, or perhaps even underlie, the formation
of conformational tau variants in tauopathies. In support of this
notion, we identified a potential 3R-tau specific strain (ac-K311
tau) that was prominent in AD and PiD, but not in CBD, PSP,
and FTLD-tau cases harboring 4R-tau, even though the K311
residue is present in all six tau isoforms capable of forming tau
inclusions (Fig. 3). Similarly, PS19 mice overexpressing human
4R-tau showed minimal ac-K311 immunoreactivity that was
only significantly induced upon HDAC6 depletion (Fig. 7a). This
indicates that 4R-tau, which has higher affinity binding to
HDAC6 compared to 3R-tau (Fig. 1f-g), may preferentially sup-
press ac-K311 immunoreactivity. In this scenario, 3R-tauopathies
would be marked by distinct acetylation profiles compared to 4R-
tauopathies, providing a unique tau PTM signature that could
explain the specific conformation and/or aggregation of dis-
tinct tau isoforms in clinically diverse neurodegenerative tauo-
pathies (see Supplementary Fig. 10 model). This could also have
important biomarker implications for distinguishing 3R from 4R
tauopathies in patient biofluids.
In summary, aberrant tau acetylation could underlie a complex
post-translational mechanism that operates in diverse human
tauopathies. Our findings identify HDAC6 as critical neuropro-
tective factor that suppresses toxic tau accumulation. Future
efforts to decipher the full tau PTM code linked to tau strain
identity could extend our understanding of tau pathogenesis and
lead to new avenues for personalized therapeutics in AD and
related disorders.
Methods
Plasmids, cell culture, and transfection. The human tau isoforms containing 0–2
N-terminal inserts and 3–4 MTBR repeats (2N4R) were cloned into pCDNA5/TO
vector (Invitrogen). Site-directed mutagenesis was used to delete residues I277/
I278/V308/V309 to generate tau 4Δ plasmids and also used to insert the indicated
familial MAPT mutations. FLAG (FL)-tagged HDAC6 (WT, 1–840, ΔBUZ) and
CBP expression plasmids (pcDNA3.1) were kindly provided by Dr. Tso-Pang Yao
(Duke University). Site-directed mutagenesis was employed to generate H216A,
H611A, and H216/611A mutants using the following primer pairs: HDAC6-216A-
F, TCCTGGACATGCCGCCCAGCACAG; HDAC6-216A-R, GGCCTAAT-
GATGGCCATG; HDAC6-H611A-F, CCCAGGACACGCCGCAGAGCAGGATG;
HDAC6-H611A-R, GGACGCACCACAGCAGCA. The ΔSE14 deletion construct
was generated using the following primers: dse14-F, CTAGCCTCGAGCACAGAC;
dse14-R, GGTGACTTTCCCCATGCC. The tau 4Δ mutation was inserted into





CACTGCCGCCTCCCGGG. The Hsp27-GFP expression plasmid was purchased
from Addgene (#17444). Hsc70-Myc, Hsp70-FL, and Hsp90-FL plasmids were
kindly provided by Dr. Jonathan Schisler (University of North Carolina,
Chapel Hill).
All described plasmids were transfected into HEK-293A cells using Fugene-6
(Promega) per the manufacturers protocols. HEK-293A cells (ThermoFisher,
#R70507) are commercially available and maintained according to standard
protocols. This cell line is a subclone of the standard HEK-293 line with a relatively
flat morphology, is more slowly growing, and maintains ectopic plasmid expression
at more physiological levels. Cells were harvested and analyzed by immunoblotting
using the antibodies listed in Supplementary Table 2. The following deacetylase
inhibitors (Sigma) were added overnight at the following final concentrations: 1 μM
trichostatin A (TSA, class I/II HDAC inhibitor), 5 μM tubastatin A (TBST, HDAC6
inhibitor), 5 mM nicotinamide (NCA, class III HDAC inhibitor).
Mice and primary neuron cultures. All protocols were carried out in accordance
with the University of North Carolina (UNC) Institutional Animal Care and Use
Committee (UNC IACUC protocol 19.017). Wild-type, HDAC6 KO, PS19, and
5xFAD strains (C57BL/6 background) aged 6–12 months old were used throughout
this study for behavior analysis. Equal male/female cohorts were analyzed in all
instances for behavior (only males were reported), histology, biochemistry, and
survival data unless indicated otherwise. For embryonic neurons, 8 week-old
female CD1 or C57BL/6 mice were used for timed pregnant breeding and cortical
neurons were dissected from E16 embryos. Breeding conditions employ a 14-h
light/10-h dark cycle with temperature range from 65 to 75 °F and 40–60%
humidity. Primary cortical neurons were genotyped and cultured from E16
embryos using 8 week-old timed pregnant female CD1 mice (Charles River), PS19
(Jackson Laboratory, #24841), or tau KO (Jackson Laboratory, #7251) (for tau re-
expression studies). Neurons were plated onto poly-D-lysine coated coverslips.
Neurons were transfected with 0.5 μg of P301L Tau-GFP and 0.5 μg of HDAC6-FL
plasmids, where indicated, using a calcium phosphate transfection kit in accor-
dance with manufacturer instructions (Takara Bio). Coverslips were fixed with 4%
paraformaldehyde (PFA) for 10 min, and cells were permeabilized by exposing
coverslips to a 0.1% Triton X-100 in 1X PBS solution for 8 min. Blocking was
performed for 1 h at room temperature in a solution of 2% milk in 1× TBS.
Following blocking, coverslips were then incubated in primary antibody overnight
at 4 °C followed by staining with an Alexa-conjugated secondary antibodies and
counterstaining with DAPI. For HDAC6 inhibition in PS19 neurons, TBST was
added overnight to neurons at 1–5 μM, where indicated, followed by harvest and
lysis as explained in immunoblotting and biochemical methods.
Immunoblotting and biochemical methods. Biochemical analyses for preparation
of lysates were performed as follows. Fractionation of cell lysates was performed by
sequential extraction using buffers of increasing strength. Cells from 6-well culture
dishes were scraped into 200 μl 1× RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl,
1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) containing 1 mM
phenylmethylsulfonyl fluoride, a mixture of protease inhibitors (1 mg/ml pepstatin,
leuptin, N-p-Tosyl-L-phenylalanine chloromethyl ketone, Nα-Tosyl-L-lysine
chloromethyl ketone hydrochloride, trypsin inhibitor; Sigma), a mixture of phos-
phatase inhibitors (1 mM NaF, 1 mM sodium orthovanadate, and 1 mM beta-
glycerophosphate; Sigma), and deacetylase inhibitors (2 µM TSA, 10 mM NCA).
Samples were sonicated 20 times and centrifuged at 21,130 × g for 30 min at 4 °C.
Supernatant was collected as the soluble fraction, and the resultant insoluble pellets
were extracted in urea buffer (7 M urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris,
pH 8.5), sonicated ten times and centrifuged at 21,130 × g for 30 min at room
temperature. Soluble and insoluble fractions were analyzed by western blotting
using primary antibodies followed by secondary HRP-conjugated antibody detec-
tion (all secondary antibodies were used at 1:500 or 1:1000 dilution unless other-
wise noted). Primary and secondary antibodies used are listed in Supplementary
Table 2. Dr. Peter Davies (Feinstein Institute for Medical Research) provided the
MC1 antibody and Dr. Tso-Pang Yao (Duke University) provided anti-HDAC6
and anti-HDAC10 antibodies. Images were captured using ImageQuant TL
v8.1 software on an LAS 4000 imager (GE Healthcare). Densitometry measure-
ments for immunoblots were performed on the ImageQuant TL Analysis Toolbox
application, where immunoblot signals were background subtracted and then
further normalized and used for quantification purposes as mentioned in figure
legends. Relative levels represent densitometry values that have been background
subtracted and then normalized to the appropriate sample group/genotype (set to
1.0) to generate a relative comparison among groups.
Human brain fractionation. Human control and AD Braak V–VI cases were
provided by the Center for Neurodegenerative Disease Research (CNDR) at the
University of Pennsylvania. Consent for autopsy was obtained from legal repre-
sentatives for all subjects in accordance with local institutional review board (IRB)
requirements. Demographics of all cases used for immunoblotting, IHC and
double-labeling IF analysis are described in Supplementary Table 1. Isolated gray
matter from frontal cortex was homogenized in 3 vol/g of cold High Salt RAB
buffer (0.75 M NaCl, 100 mM Tris, 1 mM EGTA, 0.5 mM MgSO4, 0.02M NaF, 2
mM DTT, pH 7.4). All buffers were supplemented with protease inhibitor cocktail,
phosphatase inhibitors, and deacetylase inhibitors. Homogenates were incubated at
4 °C for 20 min to depolymerize MTs, then centrifuged at 100,000 × g for 30 min at
4 °C. Pellets were rehomogenized and centrifuged in 3 vol/g of cold High Salt RAB
buffer. Resultant pellets were homogenized in 5 vol/g of cold RIPA buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate,
0.1% SDS) and centrifuged at 100,000 × g for 30 min at 4 °C. Myelin flotation was
performed on pellets re-extracted in RIPA buffer supplemented with 20% sucrose.
Finally, resultant insoluble pellets were extracted in 1 vol/g tissue in urea buffer (7
M urea, 2 M Thiourea, 4% CHAPS, 30 mM Tris, pH 8.5). Soluble and insoluble
fractions were analyzed by SDS-PAGE electrophoresis and immunoblotting using
the antibodies described in Supplementary Table 2.
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Coimmunoprecipitation assay. For coimmunoprecipitation studies, HEK-293A
cells were lysed in NP-40 lysis buffer referred to as NETN buffer (50 mM Tris-Cl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM sodium orthovanadate, 1
mM sodium fluoride, 1 mM PMSF, 0.2 mM leupeptin, protease inhibitor cocktail,
2 µM TSA, 10 mM NCA). Soluble supernatants (1 mg total protein) were cleared by
centrifugation, incubated overnight with protein A/G beads (Santa Cruz) com-
plexed to the indicated antibodies described in the figure legends, and subsequently
analyzed by SDS-PAGE and immunoblotting. Quantification of Co-IP assays were
as described in the immunoblotting and biochemical methods. Values represent a
ratio of immunoprecipitated tau to the total tau input, background subtracted, and
normalized to WT.
Antibody generation. Polyclonal anti-acetylated tau antibodies (ac-K311) were
generated using the acetylated tau peptide 307QIVYK[Ac]PVDLSKVTSC320 con-
taining acetylated K311 to immunize rabbits (Genscript, Piscataway, NJ). Double
affinity purification was performed using native and acetylated peptides. Site spe-
cificity of ac-K311 was confirmed first by peptide ELISA assays using acetylated
and unmodified peptides, and then by immunoblotting analysis of purified WT
and K311R mutant tau proteins. Highly specific polyclonal preparations from four
different rabbits were used to confirm our findings in all of the described human
studies. To validate antibody epitope reactivity, polyclonal #5089 affinity for
acetylated tau was examined and showed only minor cross-reactivity with the
K311R nonacetylated mutant (Supplementary Fig. 4), and therefore was used most
extensively throughout this study (denoted as ac-K311).
Mouse perfusions, fixation, and tissue processing. This study was performed in
strict compliance with animal protocols approved by the Institutional Animal Care
and Use Committees (IACUC) of the University of North Carolina at Chapel Hill
(UNC) under an approved protocol (#19.017). Mice were anesthetized with iso-
flurane and all efforts were made to minimize pain suffering. Mice were trans-
cardially perfused with 15 ml of phosphate-buffered saline (PBS), and brains were
removed, followed by immersion fixation for 48 h with 10% formalin in 1× PBS
and paraffin embedding, where indicated. Paraffin blocks were sectioned at 5 μm
thickness for IF and IHC analyses. Mouse brain tissue harvested for the purposes of
perfusion-fixation, brain tissue fractionation, or dot blotting was performed on 12-
month-old mice using littermates as controls.
Immunofluorescence (IF) microscopy. Double-labeling IF analyses were per-
formed using Alexa Fluor 488- and 594-conjugated secondary antibodies (Mole-
cular Probes, Eugene, OR). The sections were then treated to remove
autofluorescence with Sudan Black solution for 5 min, and secured on coverslips
with Vectashield mounting medium (Vector Laboratories). Digital images were
obtained using an Olympus BX 51 microscope (Tokyo, Japan) equipped with
bright-field and fluorescence light sources using a ProgRes C14 digital camera
(Jenoptik AG, Jena, Germany) and Adobe Photoshop, version 9.0 (Adobe Systems,
San Jose, CA) or digital camera DP71 (Olympus) and DP manager (Olympus).
For Thioflavin-S (ThS) staining, sections were deparaffinized and hydrated to
dH2O as mentioned above, followed by antigen retrieval and were rinsed in PBS,
immersed in 0.05% KMnO4/PBS for 4 min, and destained in 0.2% K2S2O5/0.2%
oxalic acid/PBS, immersed in 0.0125% ThS/40% EtOH/60% PBS and differentiated
in 50% EtOH/50%PBS for 10–15 min. After differentiation, sections were treated
for autofluorescence with Sudan Black solution for 30 s and quickly rinsed with
70% EtOH followed by wash with dH2O, incubation with DAPI, and secured on
coverslips. IF analyses were performed using Alexa Fluor 488-conjugated and 594-
conjugated secondary antibodies (Molecular Probes) and imaged with Olympus
IX83 inverted microscope. To confirm co-localization experiments, all relevant
images were separately and independently imaged on a Zeiss LSM 780 confocal
microscope. In some instances, background noise was removed from the confocal
z-stacks using the denoise function in Nikon NIS Elements software. Maximum
intensity projections of the denoised images displayed in figures were generated in
FIJI/ImageJ. All quantitative fluorescence was independently validated with a
minimum of n= 3 independent biological replicates.
Immunohistochemistry (IHC) analysis. For human studies, fixed, paraffin-
embedded tissue blocks from the midfrontal cortex were obtained from the Center
for Neurodegenerative Disease Research (CNDR) Brain Bank at the University of
Pennsylvania. The demographics of all cases are listed in Supplementary Table 1.
Consent for autopsy was obtained from legal representatives for all subjects in
accordance with local institutional review board requirements. Briefly, fresh tissues
from each brain were fixed with 70% ethanol in 150 mM NaCl, infiltrated with
paraffin, and cut into 6-µm serial sections. IHC was performed using the avidin-
biotin complex (ABC) detection system (Vector Laboratories, Burlingame, CA) and
3,3′-diaminobenzidine. Briefly, sections were deparaffinized and rehydrated, anti-
gen retrieval was done by incubating section in 88% formic acid for 5 min,
endogenous peroxidases were quenched with 5% H2O2 in methanol for 30 min,
and sections were blocked in 0.1 mol/L Tris with 2% fetal bovine serum for 5 min.
Primary antibodies were incubated overnight at 4 °C. After washing, sections were
sequentially incubated with biotinylated secondary antibodies for 1 h and ABC for
1 h. Bound antibody complexes were visualized by incubating sections in a solution
containing 100 mM TrisHCl, pH 7.6, 0.1% Triton X-100, 1.4 mM diaminobenzi-
dine, 10 mM imidazole, and 8.8 mM H2O2. Sections were then lightly counter-
stained with hematoxylin, dehydrated, and mounted on coverslips. We note that
IHC analysis of human tissue using acetylated tau antibodies requires ethanol
fixation and antigen retrieval (formic acid) for maximal detection sensitivity of tau
pathology. Double-labeling IF experiments on human tissue were performed with
antigen retrieval of 88% formic acid for 5 min followed by incubation with primary
antibodies overnight at 4 °C. Secondary Alexa Fluor 488 and 594 species-specific
conjugated secondary antibodies (Molecular Probes) were then incubated over-
night at 4 °C. Slides were treated for autofluorescence using a 0.3% Sudan Black
solution and secured by coverslips with Vectashield-DAPI mounting medium
(Vector Laboratories).
For mouse brain IHC analysis, we used the avidin–biotin complex (ABC)
detection system (Vector Laboratories) and 3,3′-diaminobenzidine. Briefly, sections
were deparaffinized and rehydrated immersed in 1× PBS pH 7.4 for 1 h. Antigen
retrieval was done by boiling sections in citrate buffer pH 6.0, endogenous
peroxidases were quenched with 5% H2O2 in water for 30 min and sections were
blocked in 0.1 M Tris with 2% fetal bovine serum for 5 min. Primary antibodies
were incubated overnight at 4 °C. After washing, sections were sequentially
incubated with biotinylated secondary antibodies for 1 h and ABC complex for 1 h.
Bound antibody complexes were visualized by incubating sections in DAB
substrate (Sigma, D3939) a solution containing 100 mM TrisHCl, pH 7.6, 0.1%
Triton X-100, 1.4 mM diaminobenzidine, 10 mM imidazole and 8.8 mM H2O2.
Sections were then lightly counterstained with hematoxylin, dehydrated, secured
on coverslips, and imaged using an Olympus BX41 microscope. The entire cortex
and hippocampus (20×) for atrophy measurements were imaged using a Nikon
EclipseTi2 inverted microscope. To assess the extent of tau pathology by IHC in
mouse brain sections, quantification of MC1, AT8, and ThS-positive neurons was
performed by counting tau-positive neurons in the hippocampus of 12-month-old
mice from n ≥ 3 mice per genotype.
Mouse brain fractionation. Fractionation of mouse brain was performed by
sequential extraction using buffers of increasing strength. Mice brain tissue was
homogenized in four volumes per gram of high-salt buffer (10 mM Tris base, 500
mM NaCl and 2 mM EDTA) supplemented with deacetylase, phosphatase and
protease inhibitors (2 µM TSA, 10 mM NCA, 1 mM NaF; 1 mM Na3VO4; 1 mM
PMSF; and protease inhibitor cocktail) and centrifuged at 21,130 × g for 45 min to
generate high-salt fractions. Resulting pellets were re-extracted in four volumes per
gram of RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA,
0.5% sodium deoxycholate, 0.1% SDS). Myelin floatation was performed on pellets
re-extracted in RIPA buffer supplemented with 20% sucrose. Finally, resultant
insoluble pellets were extracted in 1 vol/g of tissue in SDS buffer (1% SDS in 50
mM Tris, 150 mM Nacl, pH 7.6). Lysates from soluble and insoluble fractions were
analyzed by SDS-PAGE electrophoresis and immunoblotting using the indicated
antibodies from Supplementary Table 2.
Dot blotting. Mouse brain homogenates were prepared as described above.
Nitrocellulose membranes were soaked in water for 10 min before 10 μl of samples
were spotted directly on to nitrocellulose membrane using the Bio-Dot apparatus
(BioRad), and incubated at room temperature for 1 h, blocked in 2% milk in 1×
TBS for 1 h. Membranes were incubated in the primary antibody TOC1 (1:500)63
overnight at 4 °C followed by incubation with IgM-HRP-conjugated secondary
antibody for 1 h at room temperature and imaged.
Immunoprecipitation and mass spectrometry analysis. Mass spectrometry
analysis was performed at the University of Pennsylvania proteomics core facility,
which identified sites of tau acetylation and phosphorylation. Immunoprecipitation
followed by mass spectrometry was performed as follows. AD cortical lysates were
prepared as described above and soluble high salt fractions containing all six tau
isoforms were used as starting material. Total tau proteins were immunoprecipi-
tated with pooled monoclonal T14 and T46 antibodies and separated by SDS-
PAGE followed by gel excision and nanoLC/nanospray/MS/MS at the University of
Pennsylvania proteomics core facility using LTQ XL* Linear Ion Trap Mass
Spectrometer (Thermo Scientific). Data was acquired using Xcalibur software
(Thermo Scientific) and analyzed using Mascot, Scaffold, and PEAKS 6.0 (Bioin-
formatics Solutions Inc.) software packages. Significantly modified peptide cutoffs
showed p-values < 0.05 and peptide scores >20. The modified peptides isolated
from three independent AD cases with significant scores were pooled and displayed
in Table 1.
Mouse behavior. PS19 transgenic mice harbor a P301S mutant 1N4R-tau trans-
gene driven by the mouse prion promoter (PrP). Heterozygous PS19 mice on a
pure C57BL/6J background were acquired from Dr. Virginia Lee (University of
Pennsylvania) and crossed to HDAC6 KO mice acquired from Dr. Tso-Pang Yao
(Duke University)64, to generate the desired PS19-HDAC6 KO mice on a congenic
C57BL/6J background (PHK mice). The PS19 model does not show any sex-
specific differences in neurodegeneration or tau pathology, and therefore we used
male PS19 mice for all behavior analysis. 5xFAD mice harbor mutations in familial
AD genes (APP and PSEN1) and produce abundant widespread plaques that lead
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to cognitive deficits65. 5xFAD mice are commercially available from Jackson
Laboratories (#34848) and were similarly crossed to HDAC6 KO mice to generate
the desired 5xFAD–HDAC6 KO mice (5xFHK). For consistency, we similarly
analyzed male 5xFAD mice for all behavior analysis, but verified our results with
mixed cohorts including both male and female 5xFAD mice that yielded similar
results to those reported in this study. Both PS19 and 5xFAD were bred and
analyzed as heterozygotes and compared with littermates lacking one or both
HDAC6 alleles (we note that HDAC6 is an X-linked gene).
The Morris water maze was used to evaluate spatial learning and memory.
Testing was conducted by personnel that were blinded to genotype. The maze, a
large circular pool (diameter= 122 cm) partially filled with water (45 cm deep,
24–26 °C), was located in a room with numerous visual cues. The procedure
involved an initial visible platform test for vision and swimming ability, followed by
a hidden platform task for acquisition of spatial learning. For the visible platform
test, each mouse was given four trials per day, across 3 days, to swim to an escape
platform cued by a patterned cylinder extending above the surface of the water. For
each trial, the mouse was placed in the pool at 1 of 4 possible locations (randomly
ordered), and then given 60 s to find the visible platform. If the mouse found the
platform, the trial ended, and the animal was allowed to remain 10 s on the
platform before the next trial began. If the platform was not found, the mouse was
placed on the platform for 10 s, and then given the next trial. Measures were taken
of latency to find the platform and swimming speed via an automated tracking
system (Noldus Ethovision). Following the visible platform task, mice were tested
for their ability to find a submerged, hidden escape platform (diameter= 12 cm).
Each mouse was given four trials per day, with 1 min per trial, to swim to the
hidden platform. After 9 days of training, mice were given a 1 min probe trial in the
pool with the platform removed. Selective quadrant search was evaluated by
measuring percent total time spent in the target quadrant (where the platform had
been located during training) versus the opposite quadrant, and number of swim-
path crosses over the target location versus the corresponding area in the opposite
quadrant. Behavior analysis was performed in 7–9-month-old mice from PS19 and
5×FAD cohorts. In instances where mice were sacrificed after behavior analysis for
perfusion fixation and tissue harvest 12-month-old mice were used.
Recombinant tau protein purification. Purification for the following K18 frag-
ment and full length T40 recombinant tau proteins were performed, as described
below. Protein expression, extraction, and purification were performed using
chromatography methodology to purify heat stable tau proteins. Tau-K18 and tau-
T40 plasmids were cloned into the pRK172 bacterial expression vector for indu-
cible protein expression. Protein was expressed in BL21 (DE3) RIL E. coli cells.
Bacteria were grown in lysogeny broth, ampicillin was added, and when an OD of
1.0 was reached, protein expression was induced with isopropyl-β-D-thiogalacto-
pyranoside at a final concentration of 1.0 mM. After continued growth for 2 h,
bacterial cultures were then centrifuged at 2340 × g for 15 min, and pellets were
immediately frozen at −80 °C. Pellets were resuspended in a high salt RAB buffer,
pH 7.0 (0.1 M MES, 1 mM EGTA, 0.5 mMMgSO4, 750 mM NaCl, 20 mM NaF, 0.1
mM PMSF, 0.1% protease inhibitor cocktail). This resuspension was homogenized,
boiled, and centrifuged at 100,000 × g for 30 min. The resulting supernatant, with
addition of 0.1 mM PMSF and 0.1% protease inhibitor cocktail, was dialyzed
against FPLC buffer, pH 6.5 [20 mM piperazine-N,N′-bis(ethanesulfonic acid), 10
mM NaCl, 1 mM EGTA, 1 mM MgSO4, 0.1 mM PMSF and 2 mM DTT]. After
overnight dialysis, the contents were passed through a HiTrap sulfopropyl
sepharose high performance cation exchange column (GE) attached to an ÄKTA
Pure chromatography system equilibrated in FLPC buffer. Fractions were eluted
over a 0–0.4 M NaCl gradient. Portions of the fractions were separated by SDS-
PAGE and stained with Coomassie Blue R-250 (Fisher BioReagents). Fractions
containing tau protein were subsequently pooled. The FPLC buffer present in
pooled tau protein fractions was exchanged for 100 mM sodium acetate (pH 7.0),
and protein was concentrated using Amicon Ultra centrifugal filter devices (Mil-
lipore Corporation, Billerica, MA). Resultant protein concentration was deter-
mined using bicinchoninic acid assay (Thermo Scientific Pierce).
HDAC in vitro activity assays. In vitro recombinant deacetylase activity was
measured using the HDAC1 (BML-AK511), HDAC3 (BML-AK531), or HDAC6
(BML-AK516) FLUOR DE LYS fluorometric activity assay kits, per the manu-
facturer’s detailed protocol and instructions (Enzo Life Sciences). We assessed the
inhibition of deacetylase activity with the following recombinant full-length 2N4R tau
proteins: WT, P301L, L315R, S320F, and ΔR1–4 lacking the MTBR. All full-length tau
proteins were added to a final concentration of 4.36 μM, while HDACs were pre-
loaded at the following concentrations: HDAC1, 0.18 μM; HDAC3, 4.08 μM; HDAC6,
74.63 nM per the manufacturer’s protocol. Samples lacking tau but containing
HDACs and substrate represent negative controls for HDAC inhibition (100% HDAC
activity). Trichostatin A (TSA) was used as a positive control for inhibition of HDAC
activity and was employed at a final concentration of 10 nM. Deacetylase reactions
were carried out for 1 h at 30 °C, followed by the addition of developer for 45min.
Each individual HDAC assay was plotted as normalized HDAC activity relative to its
respective TSA-treatment, which was established as a relative baseline representing
maximal inhibition of HDAC activity. Fluorescence measurements were acquired
using the FLUOstar Omega microplate reader (BMG LABTECH, Germany).
Tau fibrillization assay. The extent of heparin induced aggregation was assessed
for the following recombinant K18 tau proteins: WT, P301L, K311Q, and K311R.
For each K18 tau protein, a master mix fibrillization reaction was generated and
then aliquoted into 50 μl for each time point. Fibrillization reactions were gener-
ated in the following manner: 10 μM K18 tau proteins were prepared in 100 mM
sodium acetate (pH 7.0) buffer followed by 2 mM DTT and then 10 μM heparin,
upon incubation at 37 °C. At each time point, samples were either immediately
centrifuged at 21,130 × g at 4 °C for the sedimentation assay, frozen at −80 °C for
ThT fluorescence, or processed for DLS.
Sedimentation assay. At specified time points, fibrilization reactions used for the
sedimentation assay were immediately removed from 37 °C incubation and cen-
trifuged at 21,130 × g for 30min at 4 °C to separate the soluble supernatant and
insoluble pellet fractions. Samples for the supernatant fractions were combined with
6× loading buffer and 100mM DTT, while the pellets were resuspended with 1×
loading buffer and 100mM DTT. Equal amounts of protein for each reaction and
fraction, were boiled for 10min at 98 °C and separated on 15% handcast SDS-PAGE
gels. Gels were subsequently stained with Coomassie Brilliant Blue R-250 (Fisher
BioReagents) for 30min and destained overnight for imaging.
Thioflavin T (ThT) assay. At specified time points, fibrilization reactions used for
the ThT assay were immediately removed from 37 °C incubation and frozen at
−80 °C. For the stock ThT solution, ThT was freshly prepared at 1 mM dissolved in
100 mM sodium acetate buffer, pH 7.0 and filtered to a final working solution of 10
μM ThT. In each well, 15 μl of the fibrillization reaction (or buffer) was combined
with 140 μl of 10 μM ThT for triplicate measurements per fibrillization reaction
and time point. Samples were measured at 430 nm excitation and 500 nm emission
using the FLUOstar Omega microplate reader (BMG Labtech, Germany).
Dynamic light scattering (DLS). Measurements were performed at 37 °C using a
DynaPro Dynamic Light Scattering Plate Reader (Wyatt Technology). Freshly
prepared fibrillization reactions were centrifuged at 18,390 × g for 5 min to remove
any debris, prior to loading 100 μl of sample. For each timepoint after induction of
tau fibrillization reactions, 10 acquisitions were taken and analyzed using
DYNAMICS 7.1.7.16 Software. DLS was used to monitor the presence of oligo-
meric tau species, while ThT and aggregation assays are commonly used to mea-
sure fibrillar tau aggregates that contain β-structure.
Statistics and reproducibility. For animal behavior studies, results were first
analyzed using repeated measures analysis of variance (ANOVA). Fisher’s pro-
tected least-significant difference (PLSD) tests were used for comparing group
means. Within-genotype repeated measures analyses were used to determine
learning across days of training in the hidden platform procedure, and quadrant
selectivity in the probe test. For all comparisons, significance was set at p < 0.05.
Survival analysis was calculated using a log-rank (Mantel–Cox) test to assess sig-
nificance among genotypes (WT, n= 22; HDAC6 KO, n= 42; PS19, n= 27; PHK,
n= 37). For the behavioral studies involving tauopathy mice, 7–8 month old PS19
male mice were analyzed (WT, n= 11; HDAC6 KO, n= 16; PS19, n= 15; PHK,
n= 13), while 7–9 month old 5xFAD male mice were analyzed (WT, n= 7;
HDAC6 KO, n= 7; 5xFAD, n= 8; 5×FHK, n= 10). Hippocampal atrophy mea-
surements were determined by unbiased tracing of the dentate granule layer,
CA regions, or the entire hippocampus using image-J software (WT, n= 5; PS19,
n= 7; PHK, n= 4). All cross-genotype comparisons involving three or more
genotypes were analyzed using one-way ANOVAs with Tukey’s posthoc analysis
for comparisons between the means of each group.
Significant differences from co-IP experiments, cell culture immunoblotting
experiments, and HDAC activity assays were determined by two-tailed unpaired t-
test from n= 3 independent biological replicates. Significant differences from
immunoblotting of mouse brain lysates were determined by one-way ANOVA with
Tukey’s multiple comparison or t-test with Welch’s correction from a minimum of
n= 4 mice per age group per genotype. Significant differences in protein
expression by immunoblotting of human brain lysate was determined from n= 5
AD brains using two-sided unpaired t-test with Welch’s correction. The number of
tauopathy cases analyzed by immunoblotting, IHC, and IF are described in
Supplementary Table 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper and its supplementary information files. The complete source data in this
manuscript are provided as a Source Data file. Source data are provided with this paper.
Received: 2 October 2019; Accepted: 8 October 2020;
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19317-4
16 NATURE COMMUNICATIONS |         (2020) 11:5522 | https://doi.org/10.1038/s41467-020-19317-4 | www.nature.com/naturecommunications
References
1. Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes
pathological tau aggregation. Nat. Commun. 2, 252 (2011).
2. Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant
in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23,
104–116 (2014).
3. Min, S. W. et al. Critical role of acetylation in tau-mediated neurodegeneration
and cognitive deficits. Nat. Med. 21, 1154–1162 (2015).
4. Morris, M. et al. Tau post-translational modifications in wild-type and human
amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183–1189
(2015).
5. Sohn, P. D. et al. Acetylated tau destabilizes the cytoskeleton in the axon initial
segment and is mislocalized to the somatodendritic compartment. Mol.
Neurodegener. 11, 47 (2016).
6. Tracy, T. E. et al. Acetylated Tau obstructs KIBRA-mediated signaling in
synaptic plasticity and promotes tauopathy-related memory loss. Neuron 90,
245–260 (2016).
7. Grinberg, L. T. et al. Argyrophilic grain disease differs from other tauopathies
by lacking tau acetylation. Acta Neuropathol. 125, 581–593 (2013).
8. Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to
tauopathy. Neuron 67, 953–966 (2010).
9. Arai, T. et al. Different immunoreactivities of the microtubule-binding region
of tau and its molecular basis in brains from patients with Alzheimer’s disease,
Pick’s disease, progressive supranuclear palsy and corticobasal degeneration.
Acta Neuropathol. 105, 489–498 (2003).
10. Gibbons, G. S. et al. Detection of Alzheimer disease (AD)-specific Tau
pathology in AD and NonAD tauopathies by immunohistochemistry with
novel conformation-selective Tau antibodies. J. Neuropathol. Exp. Neurol. 77,
216–228 (2018).
11. Kaufman, S. K. et al. Tau prion strains dictate patterns of cell pathology,
progression rate, and regional vulnerability in vivo. Neuron 92, 796–812
(2016).
12. Narasimhan, S. et al. Pathological Tau strains from human brains recapitulate
the diversity of tauopathies in nontransgenic mouse brain. J. Neurosci. 37,
11406–11423 (2017).
13. Min, S. W. et al. SIRT1 deacetylates Tau and reduces pathogenic Tau spread in
a mouse model of tauopathy. J. Neurosci. 38, 3680–3688 (2018).
14. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417,
455–458 (2002).
15. Kim, C. et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of
mitochondrial transport in hippocampal neurons. PLoS ONE 7, e42983
(2012).
16. Leyk, J., Goldbaum, O., Noack, M. & Richter-Landsberg, C. Inhibition of
HDAC6 modifies tau inclusion body formation and impairs autophagic
clearance. J. Mol. Neurosci. 55, 1031–1046 (2015).
17. Noack, M., Leyk, J. & Richter-Landsberg, C. HDAC6 inhibition results in tau
acetylation and modulates tau phosphorylation and degradation in
oligodendrocytes. Glia 62, 535–547 (2014).
18. Selenica, M. L. et al. Histone deacetylase 6 inhibition improves memory and
reduces total tau levels in a mouse model of tau deposition. Alzheimer’s Res.
Ther. 6, 12 (2014).
19. Zhang, L. et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer’s
disease transgenic mice. J. Alzheimer’s Dis. 41, 1193–1205 (2014).
20. Fukada, M., Nakayama, A., Mamiya, T., Yao, T. P. & Kawaguchi, Y.
Dopaminergic abnormalities in Hdac6-deficient mice. Neuropharmacology
110, 470–479 (2016).
21. Pandey, U. B. et al. HDAC6 rescues neurodegeneration and provides an
essential link between autophagy and the UPS. Nature 447, 859–863 (2007).
22. Perry, S., Kiragasi, B., Dickman, D. & Ray, A. The role of histone deacetylase 6
in synaptic plasticity and memory. Cell Rep. 18, 1337–1345 (2017).
23. Tapia, M., Wandosell, F. & Garrido, J. J. Impaired function of HDAC6 slows
down axonal growth and interferes with axon initial segment development.
PLoS ONE 5, e12908 (2010).
24. Tsushima, H. et al. HDAC6 and RhoA are novel players in Abeta-driven
disruption of neuronal polarity. Nat. Commun. 6, 7781 (2015).
25. Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation
and cell viability in response to misfolded protein stress. Cell 115, 727–738
(2003).
26. Lee, J. Y., Nagano, Y., Taylor, J. P., Lim, K. L. & Yao, T. P. Disease-causing
mutations in parkin impair mitochondrial ubiquitination, aggregation, and
HDAC6-dependent mitophagy. J. Cell Biol. 189, 671–679 (2010).
27. Govindarajan, N. et al. Reducing HDAC6 ameliorates cognitive deficits in a
mouse model for Alzheimer’s disease. EMBO Mol. Med. 5, 52–63 (2013).
28. Pasyukova, E. G. & Vaiserman, A. M. HDAC inhibitors: a new promising drug
class in anti-aging research. Mech. Ageing Dev. 166, 6–15 (2017).
29. Wang, X. X., Wan, R. Z. & Liu, Z. P. Recent advances in the discovery of
potent and selective HDAC6 inhibitors. Eur. J. Med. Chem. 143, 1406–1418
(2018).
30. Shuttleworth, S. J., Bailey, S. G. & Townsend, P. A. Histone deacetylase
inhibitors: new promise in the treatment of immune and inflammatory
diseases. Curr. Drug Targets 11, 1430–1438 (2010).
31. Yoon, S. & Eom, G. H. HDAC and HDAC inhibitor: from cancer to
cardiovascular diseases. Chonnam Med. J. 52, 1–11 (2016).
32. von Bergen, M. et al. Mutations of tau protein in frontotemporal dementia
promote aggregation of paired helical filaments by enhancing local beta-
structure. J. Biol. Chem. 276, 48165–48174 (2001).
33. von Bergen, M. et al. Assembly of tau protein into Alzheimer paired helical
filaments depends on a local sequence motif ((306)VQIVYK(311)) forming
beta structure. Proc. Natl Acad. Sci. USA 97, 5129–5134 (2000).
34. Sarkar, M., Kuret, J. & Lee, G. Two motifs within the tau microtubule-binding
domain mediate its association with the hsc70 molecular chaperone. J.
Neurosci. Res. 86, 2763–2773 (2008).
35. Boyault, C. et al. HDAC6 controls major cell response pathways to cytotoxic
accumulation of protein aggregates. Genes Dev. 21, 2172–2181 (2007).
36. Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-
dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005).
37. Scroggins, B. T. et al. An acetylation site in the middle domain of Hsp90
regulates chaperone function. Mol. Cell 25, 151–159 (2007).
38. Jinwal, U. K. et al. Imbalance of Hsp70 family variants fosters tau
accumulation. FASEB J. 27, 1450–1459 (2012).
39. Szendrei, G. I., Lee, V. M. & Otvos, L. Jr. Recognition of the minimal epitope
of monoclonal antibody Tau-1 depends upon the presence of a phosphate
group but not its location. J. Neurosci. Res. 34, 243–249 (1993).
40. Tseng, J. H. et al. The deacetylase HDAC6 mediates endogenous neuritic tau
pathology. Cell Rep. 20, 2169–2183 (2017).
41. Trzeciakiewicz, H. et al. A dual pathogenic mechanism links tau acetylation to
sporadic tauopathy. Sci. Rep. 7, 44102 (2017).
42. Guo, J. L. et al. Unique pathological tau conformers from Alzheimer’s brains
transmit tau pathology in nontransgenic mice. J. Exp. Med. 213, 2635–2654
(2016).
43. Cohen, T. J., Friedmann, D., Hwang, A. W., Marmorstein, R. & Lee, V. M. The
microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat.
Struct. Mol. Biol. 20, 756–762 (2013).
44. Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a
P301S tauopathy mouse model. Neuron 53, 337–351 (2007).
45. Zhang, Y. et al. Mice lacking histone deacetylase 6 have hyperacetylated
tubulin but are viable and develop normally. Mol. Cell. Biol. 28, 1688–1701
(2008).
46. Jicha, G. A., Berenfeld, B. & Davies, P. Sequence requirements for formation of
conformational variants of tau similar to those found in Alzheimer’s disease. J.
Neurosci. Res. 55, 713–723 (1999).
47. Jicha, G. A., Bowser, R., Kazam, I. G. & Davies, P. Alz-50 and MC-1, a new
monoclonal antibody raised to paired helical filaments, recognize
conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128–132
(1997).
48. Janczura, K. J. et al. Inhibition of HDAC3 reverses Alzheimer’s disease-related
pathologies in vitro and in the 3xTg-AD mouse model. Proc. Natl Acad. Sci.
USA 115, E11148–E11157 (2018).
49. Congdon, E. E. et al. Nucleation-dependent tau filament formation: the
importance of dimerization and an estimation of elementary rate constants. J.
Biol. Chem. 283, 13806–13816 (2008).
50. Prior, R., Van Helleputte, L., Benoy, V. & Van Den Bosch, L. Defective axonal
transport: a common pathological mechanism in inherited and acquired
peripheral neuropathies. Neurobiol. Dis. 105, 300–320 (2017).
51. Benoy, V. et al. HDAC6 is a therapeutic target in mutant GARS-induced
Charcot-Marie-Tooth disease. Brain 141, 673–687 (2018).
52. d’Ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model
of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 17,
968–974 (2011).
53. Guo, W. et al. HDAC6 inhibition reverses axonal transport defects in motor
neurons derived from FUS-ALS patients. Nat. Commun. 8, 861 (2017).
54. Landucci, E. et al. iPSC-derived neurons profiling reveals GABAergic circuit
disruption and acetylated alpha-tubulin defect which improves after iHDAC6
treatment in Rett syndrome. Exp. Cell Res. 368, 225–235 (2018).
55. Zhang, X. et al. HDAC6 modulates cell motility by altering the acetylation
level of cortactin. Mol. Cell 27, 197–213 (2007).
56. Hwang, A. W. et al. Conserved lysine acetylation within the microtubule-
binding domain regulates MAP2/Tau family members. PLoS ONE 11,
e0168913 (2016).
57. Zhang, L. et al. Proteomic identification and functional characterization of
MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase
activity. Protein Cell 6, 42–54 (2015).
58. Saito, M. et al. Acetylation of intrinsically disordered regions regulates phase
separation. Nat. Chem. Biol. 15, 51–61 (2019).
59. Croft, C. L. et al. rAAV-based brain slice culture models of Alzheimer’s and
Parkinson’s disease inclusion pathologies. J. Exp. Med. 216, 539–555 (2019).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19317-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5522 | https://doi.org/10.1038/s41467-020-19317-4 |www.nature.com/naturecommunications 17
60. Koller, E. J. et al. Combining P301L and S320F tau variants produces a novel
accelerated model of tauopathy. Hum. Mol. Genet. 28, 3255–3269 (2019).
61. Strang, K. H. et al. Distinct differences in prion-like seeding and aggregation
between Tau protein variants provide mechanistic insights into tauopathies. J.
Biol. Chem. 293, 2408–2421 (2018).
62. Carlomagno, Y. et al. An acetylation-phosphorylation switch that regulates tau
aggregation propensity and function. J. Biol. Chem. 292, 15277–15286 (2017).
63. Ward, S. M. et al. TOC1: characterization of a selective oligomeric tau
antibody. J. Alzheimer’s Dis. 37, 593–602 (2013).
64. Gao, Y. S. et al. Histone deacetylase 6 regulates growth factor-induced actin
remodeling and endocytosis. Mol. Cell. Biol. 27, 8637–8647 (2007).
65. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration,
and neuron loss in transgenic mice with five familial Alzheimer’s disease
mutations: potential factors in amyloid plaque formation. J. Neurosci. 26,
10129–10140 (2006).
Acknowledgements
Support for this work was provided by the National Institutes of Health (NIH) grants
R21AG058080 (T.J.C.), K23NS088341 (D.J.I.), National Center for Advancing Transla-
tional Sciences (NCATS) grant UL1TR001111 (T.J.C.), Alzheimer’s Association grant
NIRG-14-321219 (T.J.C.), Association for Frontotemporal Degeneration (AFTD) pilot
grant (T.J.C.), American Federation for Aging Research (AFAR) grant RAG15247
(T.J.C.), CurePSP grant 656-2018-06 (T.J.C. and D.J.I.), and NSF Graduate Research
Fellowship Program (GRFP) grant DGE-1650116 (H.T.). The Mouse Behavioral Phe-
notyping Core and the Neuroscience Microscopy Core Facility (RRID:SCR_019060) are
supported by the NIH-NICHD Intellectual and Developmental Disabilities Research
Center Grant U54 HD079124. The Neuroscience Microscopy Core Facility is also sup-
ported by funding from the NIH-NINDS Neuroscience Center Grant P30 NS045892.
M.S.I. is supported by an Imaging Scientist grant from the Chan Zuckerberg Initiative.
This work was also supported by the National Cancer Institute of the NIH award
P30CA016086. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. We would like to thank Dr. Peter
Davies (Feinstein Institute for Medical Research) for providing the MC1 antibody,
Dr. Nicholas Kanaan (Michigan State University) for providing the TOC1 antibody,
Dr. Jonathan Schisler for providing Hsp70 and Hsp90 plasmids, and Dr. Tso-Pang Yao
(Duke University) for providing HDAC6 KO mice, HDAC6 expression plasmids, and
anti-mouse HDAC6 and HDAC10 antibodies. We would also like to thank the UNC
Animal Histopathology core, the UNC Neuroscience Microscopy core, and Dr. Xu Tian
for providing excellent technical support.
Author contributions
H.T. led most aspects of the experimental study and performed the molecular, cell and
neuron based experiments, and biochemical experiments including mass spectrometry,
human tissue analysis, protein purification, and mouse immunoblotting/data analysis.
D.A. performed mouse histology experiments and assisted with immunoblotting. J.H.T.
performed HDAC6 assays, human brain I.F., primary neuron culture, and assisted with
protein purification. Y.C. assisted with plasmid preparation, mouse handling, breeding,
genotyping, perfusions, and colony maintenance. A.A. and Z.T. provided technical
assistance with immunoblotting, mass spectrometry analysis, and atrophy measurements.
R.L. and C.P. performed human tissue I.H.C. and double labeled I.F. experiments
under supervision of D.J.I. Human histology samples were reviewed and rated by D.J.I.
V.M.Y.L. and J.Q.T. provided human tissues and biochemically isolated P.H.F.-tau
extracts from human cases. S.S.M. and N.V.R. performed all mouse behavior and ana-
lysis. A.T. assisted H.T. with DLS assays. M.S.I. and H.T. performed confocal imaging to
confirm co-localization. H.T. and T.J.C. co-wrote the manuscript. This study was
directed and supervised by T.J.C.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-19317-4.
Correspondence and requests for materials should be addressed to T.J.C.
Peer review information Nature Communications thanks Janina Leyk, Rebecca Nisbet
and the other, anonymous, reviewer(s) for their contribution to the peer review of this
work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19317-4
18 NATURE COMMUNICATIONS |         (2020) 11:5522 | https://doi.org/10.1038/s41467-020-19317-4 | www.nature.com/naturecommunications
